Hsiehchen, David http://orcid.org/0000-0001-9139-302X
Bucheit, Leslie
Yang, Dong
Beg, Muhammad Shaalan
Lim, Mir
Lee, Sunyoung S.
Kasi, Pashtoon Murtaza
Kaseb, Ahmed O.
Zhu, Hao
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas
Article History
Received: 5 July 2022
Accepted: 17 November 2022
First Online: 3 December 2022
Change Date: 22 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-43052-1
Competing interests
: L.B. and D.Y. are employees of Guardant Health at the time of the analysis. M.S.B. is an employee of Science37. A.O.K. has received honoraria from Bayer Health, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, and Merck; has received consulting fees from Bayer Health, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, and Merck; has received institutional research funding from Adaptimmune, Bayer/Onyx, Bristol Myers Squibb, Genentech, Hengrui Pharmaceutical, and Merck. P.M.K. has received consulting fees from Taiho Pharmaceutical, Ipsen, Natera, Foundation Medicine, MSD Oncology, Tempus, Bayer, Lilly, Delcath Systems, Inflecton Point Biomedical Advisors, QED Therapeutics, Boston Healthcare Associates, Servier, Taiho Oncology, Exact Sciences, Daiichi Sankyo/Astra Zeneca, and Eisai; has received research funding from Advanced Accelerator Applications, Tersera, Boston Scientific. The remaining authors declare no competing interests.